Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Synthetic MR ABSYNMF 63 Buyback Yield % is -60.31 as of Jul. 15, 2026. GuruFocus rates SYNMF with a GF Score™ of 63/100 and a GF Value™ of $1.41. The stock has 3 warning signs investors should review. Among 274 Healthcare Providers & Services companies, Synthetic MR AB ranks worse than 95.26% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Synthetic MR AB's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SYNMF vs VEEV, BTSG, TEM: Buyback Yield % Comparison
For the Health Information Services subindustry, Synthetic MR AB's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synthetic MR AB Buyback Yield % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Synthetic MR AB's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Synthetic MR AB's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Synthetic MR AB (SYNMF) has a Buyback Yield % of -60.31 as of Jul. 15, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Synthetic MR AB and its competitors. According to the industry distribution chart, Synthetic MR AB ranks #261 out of 274 companies in the Healthcare Providers & Services industry, placing it in the top 95.3%.
Is Synthetic MR AB's Buyback Yield % too high?
Synthetic MR AB's current Buyback Yield % is -60.31. Based on the distribution chart, Synthetic MR AB ranks #261 out of 274 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Synthetic MR AB has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Synthetic MR AB's Buyback Yield % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Synthetic MR AB ranks #261 out of 274 companies for Buyback Yield %. This places Synthetic MR AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Healthcare Providers & Services company?
A good Buyback Yield % depends on the Healthcare Providers & Services industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Synthetic MR AB and its competitors. Synthetic MR AB's current Buyback Yield % is -60.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synthetic MR AB stock overvalued right now?
Synthetic MR AB (SYNMF) has a current Buyback Yield % of -60.31. The stock's GF Value™ is $1.41, compared to a current price of $0.19 — trading 86.8% below its estimated fair value. The current Buyback Yield % is -60.31. Synthetic MR AB's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Synthetic MR AB (SYNMF), the current Buyback Yield % is -60.31 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synthetic MR AB (SYNMF) Overvalued in 2026?
Based on GuruFocus' analysis, Synthetic MR AB stock appears to be undervalued.
The current stock price of $0.19 is trading 86.8% below its estimated GF Value™ of $1.41.
Key valuation signals for SYNMF:
Buyback Yield %: -60.31
GF Value™: $1.41 vs. price of $0.19 (86.8% below fair value)
No single metric tells the full story. See the SYNMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synthetic MR AB develops and markets software solutions that improve the efficiency of neuroimaging processes and diagnostic accuracy. SyntheticMR's SyMRI solution measures the brain's absolute tissue properties and generates multiple contrast-weighted images, performs automatic segmentation of biomarkers, and delivers quantitative data in a single rapid examination. Combinostics offers the AI-driven cNeuro product family, which helps clinicians make a difference in the lives of patients with neurological diseases. Geographically, the group operates in America, Europe, and APAC. The majority of its revenue is generated from Europe.
63GF Score
Get the complete analysis for SYNMF
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SYNMF has been successfully added to your 
